Kiniksa Pharmaceuticals, Ltd. Analyst EPS Estimates
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 1 | -$0.09 | -$0.08 | -$0.08 |
Q2 2024 | 1 | -$0.08 | -$0.07 | -$0.08 |
Q3 2024 | 1 | $0.02 | $0.02 | $0.02 |
Q4 2024 | 4 | -$0.10 | $0.23 | $0.05 |
Q1 2025 | 2 | -$0.04 | $0.20 | $0.09 |
Q2 2025 | 1 | $0.08 | $0.09 | $0.08 |
Q3 2025 | 1 | $0.13 | $0.15 | $0.14 |
Q4 2025 | 1 | $0.17 | $0.20 | $0.19 |
Kiniksa Pharmaceuticals, Ltd. Earnings Date And Information
Kiniksa Pharmaceuticals, Ltd. last posted its earnings results on Tuesday, October 29th, 2024. The company reported $-0.18 earnings per share for the quarter, missing analysts' consensus estimates of $-0.02361 by $0.15639. The company had revenue of 112.21 M for the quarter and had revenue of 270.26 M for the year. Kiniksa Pharmaceuticals, Ltd. has generated $0 earnings per share over the last year ($0.2 diluted earnings per share) and currently has a price-to-earnings ratio of -174.25. Kiniksa Pharmaceuticals, Ltd. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based on prior year's report dates.
Kiniksa Pharmaceuticals, Ltd. Earnings History by Quarter
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
10/29/2024 | Q3 2024 | -$0.02 | -$0.18 | -0.16 | $111.51 M | $112.21 M |
07/25/2024 | Q2 2024 | -$0.06 | $90.60 M | $108.63 M | ||
04/25/2024 | Q1 2024 | -$0.25 | $79.86 M | |||
02/28/2024 | Q4 2023 | -$0.11 | $0.36 | 0.47 | $83.40 M | |
11/02/2023 | Q3 2023 | -$0.20 | $64.55 M | $67.05 M | ||
08/01/2023 | Q2 2023 | $0.21 | $52.06 M | $71.47 M | ||
05/04/2023 | Q1 2023 | -$0.18 | $48.35 M | |||
03/02/2023 | Q4 2022 | $0.06 | $61.88 M | |||
11/03/2022 | Q3 2022 | $3.23 | $93.58 M | $99.14 M | ||
08/04/2022 | Q2 2022 | -$0.29 | $28.42 M | $26.97 M | ||
05/05/2022 | Q1 2022 | -$0.36 | $32.19 M | |||
02/24/2022 | Q4 2021 | -$0.53 | $18.75 M | |||
11/04/2021 | Q3 2021 | -$0.44 | $10.26 M | $12.10 M | ||
08/05/2021 | Q2 2021 | -$0.61 | $4.29 M | $7.70 M | ||
05/06/2021 | Q1 2021 | -$0.72 | $0 | |||
02/25/2021 | Q4 2020 | -$0.79 | $0 | |||
11/05/2020 | Q3 2020 | -$0.59 | -$0.66 | -0.07 | $0 | |
08/04/2020 | Q2 2020 | -$0.65 | $0 | |||
05/04/2020 | Q1 2020 | -$0.48 | $0 | |||
03/05/2020 | Q4 2019 | -$0.58 | $0 |
Kiniksa Pharmaceuticals, Ltd. Earnings: Frequently Asked Questions
-
When is Kiniksa Pharmaceuticals, Ltd.'s earnings date?
Kiniksa Pharmaceuticals, Ltd. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based off last year's report dates.
-
How can I listen to Kiniksa Pharmaceuticals, Ltd.'s earnings conference call?
The conference call for Kiniksa Pharmaceuticals, Ltd.'s latest earnings report can be listened to online.
-
How can I read Kiniksa Pharmaceuticals, Ltd.'s conference call transcript?
The conference call transcript for Kiniksa Pharmaceuticals, Ltd.'s latest earnings report can be read online.
-
How much revenue does Kiniksa Pharmaceuticals, Ltd. generate each year?
Kiniksa Pharmaceuticals, Ltd. (:KNSA) has a recorded annual revenue of $270.26 M.
-
How much profit does Kiniksa Pharmaceuticals, Ltd. generate each year?
Kiniksa Pharmaceuticals, Ltd. (:KNSA) has a recorded net income of $270.26 M. Kiniksa Pharmaceuticals, Ltd. has generated $0.2 earnings per share over the last four quarters.
-
What is Kiniksa Pharmaceuticals, Ltd.'s price-to-earnings ratio?
Kiniksa Pharmaceuticals, Ltd. (:KNSA) has a price-to-earnings ratio of -174.25 and price/earnings-to-growth ratio is -8.71.